Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15252430 | 1.00 | MAPT (0.44) | MAPTXBP1NPSR1TDP1CTSK | |
| SCHEMBL15251664 | 1.00 | MAPT (0.44) | MAPTXBP1NPSR1TDP1CTSK | |
| SCHEMBL7439259 | 0.84 | L3MBTL1 (0.43) | MAPTXBP1NPSR1TDP1CTSK | |
| SCHEMBL15251844 | 0.84 | L3MBTL1 (0.41) | MAPTXBP1NPSR1TDP1CTSK | |
| SCHEMBL27853183 | 0.84 | L3MBTL1 (0.41) | MAPTXBP1NPSR1TDP1CTSK | |
| SCHEMBL27853178 | 0.83 | CTSK (0.48) | MAPTXBP1NPSR1TDP1CTSK | |
| SCHEMBL13519510 | 0.83 | CTSK (0.48) | MAPTXBP1NPSR1TDP1CTSK | |
| SCHEMBL15251727 | 0.80 | FKBP1A (0.47) | CTSL | |
| SCHEMBL15251728 | 0.80 | FKBP1A (0.47) | CTSL | |
| SCHEMBL15251813 | 0.79 | AAK1 (0.37) | CTSKCTSBCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3466961-A1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | Li, Min (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9434760-B2 | Prolinamide derivatives as thrombin inhibitors, preparation method and application thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-09-06 | — | — | US | disclosed |
| EP-2824097-A1 | Prolinamide derivative as thrombin inhibitor, preparation method and application thereof | Shanghai Institute of Pharmaceutical Industry (CN) | 2015-01-14 | — | — | EP | disclosed |
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-11-07 | — | — | US | disclosed |
| EP-2639230-A1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Pharmaceutical Industry (CN) | 2013-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | PREP, TFPI, PEPD | MAPT 3609/4885XBP1 1002/4885NPSR1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.